Amarin To Acquire Ester Neurosciences, Gain Clinical-Stage Neuromuscular Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Amarin CEO Stewart tells “The Pink Sheet” DAILY about the company’s partnering strategy for neurology and cardiovascular drugs.